K-Cast

In this discussion on vitiligo, Seemal Desai, M.D., FAAD, explores disease mechanisms, diagnostic approaches, emerging therapies, treatment optimization, managed care considerations and psychosocial support strategies, emphasizing personalized care while addressing access barriers and the integration of digital health technologies to improve patient outcomes.

Sean M. Oser, MD, MPH, discusses strategies for optimal diabetes management.

Arwen Podesta, MD, explores prescription digital therapeutics as a solution for addressing unmet needs in patients with mental health conditions.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, provides clinical insights on the treatment of myelofibrosis, highlighting currently available therapies, ongoing research, and cost concerns.

Insights surrounding intravenous and subcutaneous biologic therapy utilization are presented by medical experts.

Paul W. Noble, MD, discusses key updates in treatment for idiopathic pulmonary fibrosis.

Lawrence Eichenfield, MD, provides insights on the treatment of atopic dermatitis, highlighting its impact on patients, the evolving therapeutic landscape, and areas of unmet need.

Selina McGee, OD, FAAO, investigates the clinical implications of Demodex blepharitis and its impact on patient well-being, considering the wide range of symptoms and potential secondary complications, while also reviewing the latest FDA-approved therapy.

Mahsa Salsabili, PharmD, PhD, explores the current landscape and potential optimization strategies for prescription digital therapeutics by payers and providers in managing various conditions, including diabetes, chronic pain, addiction, and behavioral health disorders.

Joseph Chervenak, MD, MBA, analyzes psychosocial, socioeconomic, and clinician-specific challenges associated with reproductive medicine treatment.

Christopher Starr, MD, FACS, provides an overview of current challenges and key treatment options for Demodex blepharitis.

An expert discusses how payers and providers are embracing biosimilars and unbranded biologics as they enter the marketplace.

James Lewis, PharmD, FIDSA, discusses vaccine hesitancy, vaccination status, and accessibility to vaccines across various patient populations.

Medical experts highlight key factors impacting the treatment landscape of spinal muscular atrophy (SMA).

Douglas K Devries, OD, discusses an overview on treatment pathways and burden of disease associated with Demodex blepharitis.

Dr David Rosmarin, MD, explores the treatment landscape and clinical burden associated with vitiligo.

A discussion series reviewing the differences between unbranded biologics and biosimilars and an overview of payer and provider considerations for decision-making.

This content is a production of Managed Healthcare Executive; distribution of this K-Cast is supported by funding from CSL Behring LLC. CSL Behring LLC was not involved in the creation of the content of this production.

Steven Pipe, MD, discusses the treatment options for patients with hemophilia B, including his hope for future management of the bleeding joint disease.

Dr Laura Periman, MD discusses biopsychosocial and economic impacts, as well as innovative treatment opportunities for patients with dry eye disease.

Neal Bhatia, MD, discusses atopic dermatitis and the treatment process, as well as how to improve access to therapies for patients with this disease.

Jennifer Brigitte Green, MD, discusses the management of type 2 diabetes for patients not currently controlled on oral antidiabetic medications.

Expert hematologist/oncologist David R. Gandara, MD, highlights the value comprehensive genomic profiling has in guiding therapeutic decisions.

Recommendations for treating HER2-positive metastatic breast cancer with newer HER2-targeted treatment approaches and considerations regarding their adoption into clinical practice.

Paul K. Paik, MD, discusses the spectrum of targeted therapy in non-small cell lung cancer.

Key opinion leader discusses considerations for adult patients with spinal muscular atrophy (SMA) including disease burden, treatment evaluation, and the use of real-world evidence.